Research Article

Anti-Dengue, Cytotoxicity, Antifungal, and In Silico Study of the Newly Synthesized 3-O-Phospho-α-D-Glucopyranuronic Acid Compound

Tareq Abu-Izneid,1,2 Abdur Rauf,3 Saud Bawazeer,1 Abdul Wadood,4 and Seema Patel5

1Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
2Department of Pharmaceutical Sciences, College of Pharmacy, Al Ain University of Science and Technology, Al Ain Campus, UAE
3Department of Chemistry, University of Swabi, Khyber Pakhtunkhwa, Pakistan
4Department of Pharmacy, Abdul Wali Khan University, Mardan, Pakistan
5Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego, USA

Correspondence should be addressed to Tareq Abu-Izneid; tizneid@gmail.com and Abdur Rauf; mashaljcs@yahoo.com

Received 23 June 2018; Revised 21 October 2018; Accepted 8 November 2018; Published 3 December 2018

Academic Editor: Marcelo A. Soares

Copyright © 2018 Tareq Abu-Izneid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of the current study was to synthesize new bioactive compounds and evaluate their therapeutic relevance. The chemical structure of compound 7 (methyl 3-O-phospo-α-D-glucopyranuronic acid was elucidated by physical and advance spectral technique. Also, this compound was assessed for various in vitro biological screening. The results showed that compound 7 has promising antifungal activity against selected fungal strains. Computational study was also carried out to find antimalarial efficacy of the synthesized compounds. Compounds (2-7) were tested for cytotoxicity by MTT assay, and no considerable cytotoxicity was observed. Molecular docking study was performed to predict the binding modes of new compound (7). The docking results revealed that the compound has strong attraction towards the target protein, as characterized by good bonding networks. On the basis of the acquired results, it can be predicted that compound (7) might show good inhibitory activity against dengue envelope protein.

1. Introduction

Viruses are a major cause of diseases worldwide. Hepatitis C virus (HCV), human papillomavirus (HPV), influenza virus, herpes simplex virus (HSV), Japanese encephalitis virus, rotavirus, human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), and Ebola virus are some of the most common pathogenic viruses. While HIV is largely contained in recent years, the emergence of dengue virus, Ebola virus, and Zika virus has been very alarming. Viruses bind to cell surface heparan sulfate proteoglycans and enter into the host cells. Viral proteases bind to host mannan binding lectins (MBL), the pattern recognition molecules, which leads to the activation of complement system [1–3]. The complement system includes serum proteins, receptors, and proteases. This system assists the antibodies and phagocytic cells in immune defense. But excess or perpetual activation of the complement system creates an inflammatory milieu and can cause blood coagulation.

Numerous phytochemicals have shown different degrees of inhibitory responses towards various pathogenic viruses. Polyphenols, alkaloids, sulfated polysaccharides, and glycosides among others have shown in vitro antiviral responses. In a study, cardiac glycosides inhibited HIV-1 gene expression, preventing the viral assembly, by manipulating Na-K-ATPase pump action [4]. Lanatoside C, a cardiac glycoside, has showed inhibitory effect on all four serotypes of dengue virus [5]. Polyphenolic compounds, flavonoids, chalcones, and other phenolics were the common docking ligands for dengue virus protein targets such as protease (NS2B-NS3pro), helicase (NS3 helicase), methyltransferase (MTase), RNA-dependent RNA polymerase (RdRp), and the
dengue virus envelope protein [6]. Deacetyl-3-cinnamoyl-
Azadirachta indica inhibited NS3/4A pro-
tase of HCV [7].

Glucuronide or glucuronoside is glucuronic acid bound
to other moieties by glycosidic bond. In fact, glucuronides are
glycosides. Glucuronide derivatives constitute an important
class of pharmaceutical active compounds which possess
antiviral activity. Amantadine glucuronide and its derivative
when combined with rimantadine inhibited the reproduction
of influenza virus strains A/H1N1 and A/H3N2 [8]. Influenza
virus inhibitory activities of spacer-linked 1-thioglucuronide
analogues of glycyrrhin have been observed [9].

In a study glucuronide 3-O-sulfated GlcA interfered with
the binding of dengue virus to host cell receptors [10].
Further, this glucuronide had low cytotoxicity and it was
effective at EC50 value lower than that of sucrose octasulfate,
an inhibitor of dengue virus infection [10].

Hence, the aim of current finding was to synthesize
methyl 3-O-phospho-α-D-glucopyranuronic acid, to conduct
in silico analysis, and to predict pharmaceutical relevance.

2. Experimental

2.1. Material and Methods. The chemical and reagents used
in this study were of analytical grade. The methylglucoside,
1-O-methyl glucose (I), was purchased from Sigma Aldrich.
IR spectra were recorded on a FT-IR Nicolet 380 spec-
trophotometer (UK), as KBr disks, from 400-4000. 1H-NMR
spectra were measured on AVANCE AV600 Crycprob
spectrometer in CDCl3. Mass spectra were recorded by using
JEOL-600H-2 mass spectrometer; EI source 70 eV.

2.2. Synthesis of Methyl 3-O-Phospho-α-D-Glucopyranuronic
Acid (7). Methyl 3-O-phospho-α-D-glucopyranuronic acid
(7) (Scheme 1) was synthesized by using the following
procedure. 1-O-Methyl glucose 1 (1.00 mmol) was reacted
with benzaldehyde (1.00 mmol) in tetrahydrofuran (THF; 1.00 mmol) as per standard procedure [10] and then reacted
with benzyl chloride (1.00 mmol), in dimethylformamide
(DMF; 1.00 mmol) in basic media (NaOH; 1.00 mmol) to
obtain intermediate [11, 12]; then reaction mixture was
refluxed for 48-72 h to obtain compound 2. To synthesize
compound 3, compound 2 (1.00 mmol) was reacted with
di-Fm-phosphoramidite (1.00 mmol) in presence of 1H-
tetrazole (1.00 mmol) and then oxidized with hydrogen
peroxide [10]. Compound 3 (1.00 mmol) is then reacted
with pieridine to disconnect the Fm group, which presented
compound 4. Compound 4 after acidic work-up resulted in
compound 5. Compound 5 (1.00 mmol) was reacted with
triethylsilane and 10% Pd/C in methanol at 25°C followed by
oxidation of primary alcohol [10], which generated methyl
3-O-phospho-α-D-glucopyranuronic acid (7) Yield; 700 mg
(37%). The residue obtained in each step was purified by
normal phase chromatography over silica gel by using chlo-
roform: methanol as a solvent system. The purity of the
compounds was confirmed by TLC. The structure of identi-
fied compounds was confirmed by comparing their spectral
data with reported one [10].

2.3. Methyl 3-O-Phospho-α-D-Glucopyranuronic Acid (7).
White needle solid; yield: 90 mg, 65%, IR; 3443.50 for OH
stretching, 2919.21 CH stretching, 2875.07 C=O stretching
and 1682, 24, COOH stretching. EI-MS; 287, 3H-NMR (600
MHz, CDCl3); δH 5.01 (d, H-1, J=3.00), 3.58 (d, H-2, J=9.6),
4.36 (d, J=9.6, J=9.6), 3.56 (d, H-4, J=9.6), 4.56 (d, H-5, J=9.6)
and 3.29 (s, OCH3).

3. Biological Activity

3.1. Cytotoxicity Study by MTT Methods. In vitro cyto-
toxicity study of the compounds (2-7) was performed by using
mice hepatocytes and LCMK-2 monkey kidney
epithelial cells [13]. Incubation of the compounds (2-
7) was achieved in 24h and subsequently the cell abil-
ity was recognized by MTT (3-[4,5-dimethylthiazol-2-yl]-2-
diphenyltetrazolium bromide) method. In this procedure, the
cells were kept in RPMI-1640 medium which was acquired
from Gibco BRL. This medium comprises 110 µg/ml penicillin
sodium salt, 2 mg/ml sodium bicarbonate (NaCO3), 10%
fetal bovine serum (FBS), and 100 µg/ml streptomycin sulfate.
Initial seeding of the 7.1×10⁵ LCMK-2 cells and 8.6× 10⁵ mice
hepatocytes was performed in 96-well plates. The cells were
treated with the synthesized compounds (2-7) at different
concentrations and also with a vehicle containing 0.2 %
DMSO. Subsequently, they were subjected to incubation
for 48h followed by conducting MTT assays.

3.2. Antifungal Activity. The antifungal properties of com-
ounds (2-7) were assayed according to standard procedure.
The tube dilution assay was performed to determine the
fungal inhibitory effect of the compounds. Each compound
was dissolved in DMSO at 2µg/ml to prepare stock solution.
SDA (Sabouraud dextrose agar) (4 ml) were poured into
each tube and autoclaved for 15 min at 120°C and then
allowed to cool at 15°C. To the SDA medium, stock solution
(66.6 µL) was added, which gave the final concentration
2mg/mL. All tubes were allowed to solidify in the slanted
position at room temperature. Each tube was incubated
with inoculum removed from a 7-day-old culture of fungal strain.
The antifungal activity of each sample and standard drug was
recorded after 7 days of incubation. The antifungal activity
was performed in triplicate. Then the results were analyzed
for the visible growth of fungi and % activity was calculated.

3.3. Molecular Docking. Molecular docking was carried out
to predict the binding modes of newly synthesized 3-O-
phosphated glucuronide derivative in the binding pockets
dengue virus envelope protein and antifungal enzymes.
The 3D structures of dengue virus entry protein (PDB
ID: IOKE) and antifungal enzymes, dihydrofolate reduc-
tase (PDB ID: 4HOF), aspartic protease (PDB ID: 3Q70),
and N-myristoyl transferase (PDB ID: 1LYL), were down-
loaded from protein databank (http://www.rcsb.org/) [14].
The 3D structures were then subjected to protonation and
energy minimization, using default parameters of MOE
(http://www.chemcomp.com/) [15]. The three-dimensional
structure of 3-O-phosphated glucuronide derivative (7) was
built by using Molecular Builder Module program implemented in MOE and saved as a (.mdb) file for molecular docking. Subsequently, the energy of the built compound was minimized up to 0.05 gradient using MMFF94s force field implemented in MOE. The modelled compound was docked into the active site of proteins using the Triangular Matching docking method (default) and 10 different conformations were generated. To obtain minimum energy structures, the ligand was allowed to be flexible during docking. At the end of docking, the predicted ligand-protein complexes were analyzed for molecular interactions.

4. Results and Discussion

4.1. Interaction of Compound with Dengue Envelope Protein. Previous research had showed that the crystal structure of soluble ectodomain of dengue virus 2 envelope has a hydrophobic pocket present in the hinge region between domains I and II [16]. This hydrophobic pocket binds to n-octyl-β-D-glucoside or β-OG (a small detergent molecule); therefore, it is known as β-OG binding site and it is proposed as an appropriate target for developing small molecule inhibitors of viral host fusion process [17]. This pocket is important for the low-pH-triggered conformational rearrangement during fusion [16]. So, compounds blocking the β-OG binding site interfere with conformational changes in the envelope protein [18]. The sequence similarity among four different dengue serotypes was carried out using NCBI BLAST. Result showed that the sequence of dengue virus envelope protein 1OKE is almost identical with other DENV-2 sequences found in the NCBI website, with identity score about 99%. However, the identity of 1OKE sequence and other types of DENV sequences falls between 69% and 54%, with the least identity obtained when 1OKE was compared with the envelope protein of DENV-4. The higher the identity of two or more sequences, the more similar their protein structure is. If the target proteins share the identity of 50%, their protein structure is sufficiently reliable for drug design purpose [19].

The docking results showed that the newly synthesized compound 7 was well-accommodated in the binding pocket of β-OG. The docking scores for reference compound (octyl- β-OG) and compound 7 were -7.0046 and -5.6691, respectively. The docking conformation of compound 7 in the hydrophobic pocket of envelope protein showed that this compound established five polar interactions and three hydrophobic interactions (Figure 1(a)). The polar interactions were established between the oxygen atoms of compound 7 and the active site residues Glu49, Thr48, Ala50, Gln200, and Gln271 of the envelope protein. Compound 7 showed hydrophobic interactions with the nonpolar residues Ala50, Leu198, and Leu277 (Figure 1(a)). On comparison of the binding mode of the synthesized compound with the reference compound (cocrystallized compound), it was observed that both compounds showed about similar binding modes with dengue envelope protein (Figure 1(b)). The docking results showed that the synthesized compound has strong affinity with the target protein, as represented by good bonding networks with the target protein. On the basis of the obtained results, we can predict that this compound might show good inhibitory activity against dengue envelope protein.

4.2. Antifungal Activity. Antifungal activity of the synthesized compounds (2-7) was measured as per standard procedure. The results indicated that compounds 2-7 exhibited excellent reduction in the growth of selected fungal strains. Among all tested compounds, compound 7 exhibited maximum effect (35-45 mm) against Aspergillus flavus, Candida albicans, and Fusarium solani. Compounds 2-6 showed moderate activity (10-35 mm) against selected fungal strains (Table 1). Hence, the results suggest environmentally friendly treatment avenue for fungal infections.

4.3. Docking against Antifungal Enzymes. To validate and specify the drug target for antifungal activity of these compounds, three different target proteins from C. albicans were selected as antifungal targets. Among them, only one target protein, i.e., dihydrofolate reductase (DHFR) from C. albicans, was preferred as it showed good docking score (-5.8605) and interactions with compound 7, as compared to secreted aspartic protease (4.9656) and N-myristoyl transferase (4.7592) in docking simulation.

The docking conformation of compound 7 in the binding pocket of DHFR showed that this compound establishes seven hydrogen bonds with the active site residues Val10, Met25, Trp27, Glu32, Ile33, and Tyr118 of DHFR (Figure 2). This compound also formed hydrophobic interaction with...
Table 1: Antifungal activity of compounds 2-7.

| Name of the fungus | 2  | 3  | 4  | 5  | 6  | 7  | STD | MIC (µg/ml) |
|-------------------|----|----|----|----|----|----|-----|------------|
| A. flavus         | 30 ± 1.44 | 30 ± 1.14 | 25 ± 1.48 | 28 ± 1.88 | 35 ± 2.06 | 44 ± 1.16 | Amphotericin B | 20.20 |
| C. albicans       | -  | -  | -  | -  | -  | -  | 45 ± 1.17 | Miconazole | 110.8 |
| C. glabrata       | 18 ± 1.20 | 15 ± 1.46 | 18 ± 1.28 | 20 ± 2.27 | -  | -  | Miconazole | 110.8 |
| E. solani         | -  | -  | 20 ± 1.20 | 15 ± 1.88 | 10 ± 2.00 | 35 ± 1.49 | Miconazole | 110.2 |
| M. canis          | 20 ± 2.00 | 18 ± 1.01 | -  | -  | -  | -  | Miconazole | 98.4 |
| T. logifusus      | 15 ± 1.24 | 30 ± 2.02 | -  | -  | -  | -  | Miconazole | 100.5 |

4.4. Cytotoxic Effect. Compounds (2-7) were assessed for their cytotoxicity by using MTT assay. No considerable cytotoxicity was observed.

4.5. Antifungal Effect. The results of the antifungal activity of compounds (2-7) are illustrated in Table 1. Among all the tested compounds, compound 7 showed good antifungal activity against A. flavus, C. albicans, and F. solani with % zone of inhibition which ranges in 35-45 mm, followed by compounds 2-6 (Table 1). The current finding demonstrated wide antifungal potency of compound 7 followed by compounds 2-6 against selected pathogenic fungi.

5. Conclusion

The current finding describes the synthesis, characterization, in vitro antifungal, cytotoxicity, and in silico anti-dengue study of methyl 3-O-phospho-α-D-glucopyranuronic acid (7). The results showed that compound 7 has promising antifungal activity against selected fungal strains. Cytotoxicity was negligible. The docking showed that compound (7) has strong attraction towards the target protein, characterized by good active site residues Ala11, Leu29, Phe36, and Ile12. This strong bonding network might be one of the reasons for this compound’s good antifungal activity.
bonding networks. On the basis of the developed results, we can predict that compound (7) might show good inhibitory activity against dengue envelope protein.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflict of interest regarding the publication of this paper.

**Authors’ Contributions**

Tareq Abu-Izneid and Abdur Rauf supervised the project and conducted the experimental part. Abdul Wadoor performed the docking analysis. Seema Patel and Saud Bawazeer were involved in editing and they gave the final shape to this manuscript. All authors read the paper and approved it for submission.

**Acknowledgments**

The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University (Baith Program, Grant Code: 15-MED-3-1-0026, Investigators: Dr. Tareq Abu-Izneid and Dr. Saud Bawazeer) for the financial support.

**References**

[1] N. Drentin, P. Conroy, M. J. Gunzburg, R. N. Pike, and L. C. Wijeyewickrema, "Investigation of the mechanism of interaction between Mannose-binding lectin-associated serine protease-2 and complement C4." Molecular Immunology, vol. 67, no. 2, pp. 287–293, 2015.

[2] A. Saeed, K. Baloch, R. J. P. Brown et al., "Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells," Clinical & Experimental Immunology, vol. 174, no. 2, pp. 265–273, 2013.

[3] M. Takahashi, S. Mori, S. Shigeta, and T. Fujita, "Role of MBL-associated serine protease (MASP) on activation of the lectin complement pathway," Advances in Experimental Medicine and Biology, vol. 598, pp. 93–104, 2007.

[4] G. M. Laird, E. E. Eisele, S. A. Rabi, D. Nikolaeva, and R. F. Siliciano, "A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides," Journal of Antimicrobial Chemotherapy, vol. 69, no. 4, Article ID dkt471, pp. 988–994, 2014.

[5] Y. Y. Cheung, K. C. Chen, H. Chen, E. K. Seng, and J. J. H. Chu, "Antiviral activity of lanatoside C against dengue virus infection," Antiviral Research, vol. 111, pp. 93–99, 2014.

[6] C. N. Powers and W. N. Setzer, "An in-silico investigation of phytochemicals as antiviral agents against dengue fever," Combinatorial Chemistry & High Throughput Screening, vol. 19, no. 7, pp. 516–536, 2016.

[7] U. A. Ashfaq, A. Jalil, and M. T. ul Qamar, "Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach," Natural Product Research (Formerly Natural Product Letters), vol. 30, no. 16, pp. 1866–1869, 2016.

[8] J. Serkedjieva and I. Zgoniak-Nowosielska, "Combined antinfluenza activity of a plant preparation SHS-174 and amantadine derivatives," Acta Viroligica, vol. 37, no. 4, pp. 258–264, 1993.

[9] C. Stanetty, A. Wolkerstorfer, H. Watnabe et al., "Synthesis and antiviral activities of spacer-linked 1-thioglucuronide analogues of glycyrrhizin," Beilstein Journal of Organic Chemistry, vol. 8, pp. 705–711, 2012.

[10] K. I. P. J. Hidari, K. Ikeda, I. Watnabe et al., "3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent," Biochemical and Biophysical Research Communications, vol. 424, no. 3, pp. 573–578, 2012.

[11] D. M. Clode and D. M. Clode, "Carbohydrate Cyclic Acetal Formation and Migration," Chemical Reviews, vol. 79, no. 6, pp. 491–513, 1979.

[12] C. Herbivo, Z. Omran, J. Revol, H. Javot, and A. Specht, "Synthesis and characterization of cell-permeable caged phosphates that can be photolyzed by visible light or 800 nm two-photon photolysis," ChemBioChem, vol. 14, no. 17, pp. 2277–2283, 2013.

[13] G. Uddin, A. Rauf, M. Arfan et al., "Pistagreem acid a new leishmanicidal triterpene isolated from Pistacia integerrima Stewart," Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 27, no. 5, pp. 646–648, 2012.

[14] "The Protein Data Bank," in Structural Bioinformatics, Methods of Biochemical Analysis, pp. 181–198, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2003.

[15] "Molecular Operating Environment (MOE)," in Chemical Computing Group Inc, Montreal, QC, Canada, 2016.

[16] E. S. Leal, M. G. Aucar, L. G. Gebhard et al., "Discovery of novel dengue virus entry inhibitors via a structure-based approach," Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 16, pp. 3851–3855, 2017.

[17] Y. Modis, S. Ogata, D. Clements, and S. C. Harrison, "A ligand-binding pocket in the dengue virus envelope glycoprotein," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 12, pp. 6986–6991, 2003.

[18] M. K. Poh, A. Yip, S. Zhang et al., "A small molecule fusion inhibitor of dengue virus," Antiviral Research, vol. 84, no. 3, pp. 260–266, 2009.

[19] A. Hillisch, L. F. Pineda, and R. Hilgenfeld, "Utility of homology modeling in the drug discovery process," Drug Discovery Therapy, vol. 9, no. 15, pp. 659–669, 2004.